SCHEMBL7914456

SCHEMBL7914456

O=c1c(OCCl)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLH Q9Y253 8/20 0.79
▸ MEN1 O00255 4/20 0.72
▸ KMT2A Q03164 4/20 0.72
▸ KDM4E B2RXH2 4/20 0.72
▸ POLB P06746 4/20 0.72
▸ GAA P10253 4/20 0.72
▸ RECQL P46063 3/20 0.72
▸ HSD17B10 Q99714 3/20 0.72
▸ MAPT P10636 3/20 0.72
▸ MMP1 P03956 2/20 0.72
▸ APEX1 P27695 2/20 0.72
▸ BLM P54132 2/20 0.72
▸ HTT P42858 1/20 0.72
▸ EPHX2 P34913 3/20 0.65
▸ NOX4 Q9NPH5 3/20 0.65
▸ AKR1B1 P15121 3/20 0.65
▸ USP2 O75604 2/20 0.65
▸ TP53 P04637 2/20 0.65
▸ CYP1A2 P05177 2/20 0.65
▸ CYP3A4 P08684 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10728956 0.88 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL7202826 0.88 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL13554247 0.88 POLB (0.65) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL14786208 0.86 POLH (0.81) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL25304942 0.86 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL17620378 0.86 POLH (0.89) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL30663836 0.86 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL3029675 0.86 POLH (0.76) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL28067122 0.86 POLH (0.76) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL10621095 0.85 POLH (0.74) POLHMEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234310-A1 ESTROGENIC COMPOUNDS AND THEIR METHODS OF USE BIONOVO, INC. (US) 2010-09-16 — — US disclosed
WO-2010104691-A2 ESTROGENIC COMPOUNDS AND THEIR METHODS OF USE BIONOVO, INC. (US) 2010-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234310-A1 ESTROGENIC COMPOUNDS AND THEIR METHODS OF USE ESR1, GPER1, ESR2 POLH 2072/4885MEN1 507/4885KMT2A 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback